Rxlogix Corporation
Delivering Nexgen Pharmacovigilance Solutions

November 19, 2018, was a day to cherish for Raj More, the CEO and Chief Architect of RxLogix Corporation, and his team. The FDA had selected RxLogix’s PV Signal and PV Reports as components of an integrated drug safety platform to support the agency’s pre-and post-market surveillance operations. The FDA chose these products to conduct data analysis, signal detection, evaluation, and signal management on safety data, by replacing their legacy FAERS data analytics system with commercial off-the-shelf (COTS) products. FDA selected RxLogix’s offerings after a thorough evaluation of several commercially available data analytics and signaling software.

For RxLogix, this achievement didn’t come easy. The exceptional strength and resilience the company has shown since its inception has, in many ways, set the ball rolling for its historic partnership with the FDA.

The collaboration cemented RxLogix’s position as the most innovative company that develops user-friendly Pharmacovigilance (PV) systems. “It was a huge opportunity for us, and it was gratifying to see our hard work paying off,” says Raj More.

A Renewed Take on Pharmacovigilance

RxLogix was established with a vision to provide pharmaceutical companies with efficient and trusted services. The concept was to become a go-to partner for pharma companies to entrust all their PV tasks. As Raj explains, “a few teammates and a couple of customers took a massive gamble on our concept. They had the solid trust that our products are compliant with all regulations, can ensure safe and timely studies, and can secure the information.” As the first few customers and close peers gave a chance to the ‘new kid on the block,’ RxLogix Corporation bootstrapped itself and started its journey. “It has certainly been a roller coaster ride with ups and downs,” Raj adds.

Today, RxLogix is a one-stop-shop for all PV needs, offering a full PV line of products to answer their clients’ security and safety requirements. “We are privileged to have such great allies and work with people who share the same vision and passion as we do,” states Raj.

RxLogix applies the most recent technological advances such as machine learning, artificial intelligence, and best practice methodological approaches. The company’s experienced team of business and technology innovators works with PV and risk management professionals to help increase the compliance, productivity, and quality of the entire drug safety value chain.

Comprehensive PV Product Offerings

RxLogix offers every product needed by pharmaceutical companies to protect, secure, and monitor their assets. The company’s innovative products are intelligent, sophisticated, intuitive, and simple to operate, requiring little training.

We are privileged to have such great allies and work with people who share the same grand vision and passion as we do

“Our products address all aspects of case intake, reporting, analytics, signal detection, and management requirements through an easy, user-friendly interface,” mentions Shalini Modi, COO of RxLogix. The compelling applications that are tailor-made for drug safety in the pharma industry are available to clients using the Software as a Service (SaaS) delivery method. The cost-effective method provides value to all biotech, CRO, and pharma companies, big or small.

RxLogix’ ‘range of solutions are comprehensively modular, and they have been perfectly packaged to address the various nuances pertaining to PV.

While PV Intake is one of the most efficient, compliant, and cost-effective solutions for Case Intake System and Safety integration, PV Reports and PV Central offer a one-stop integrated PV reporting and analytics solution and global compliance and productivity monitoring, respectively. The PV Signal product is a comprehensive, compliant, and user-friendly signal detection and management solution. PV Analytics Suite is the world’s first holistic and integrated pharmacovigilance solution addressing all aspects of reporting, analytics, signal detection, and management in a highly user-friendly manner. Further, PV E2B-Converter is a must-have solution for non-E2B (R3) compliant PV systems. It seamlessly allows companies to comply with E2B (R3) without going through an expensive and time-consuming upgrade. And PV Publisher tool provides an end-to-end solution for aggregate reports processing for both PV and clinical groups. It also offers rich features for document review and co-authoring for the delivery of high-quality documents.

Further, RxLogix’ PV Quality is a safety, data-quality management solution that enables safety operations managers to detect case processing quality issues and implement corrective and preventative actions. It is designed for companies to improve data quality and drive consistency across their case processing operation, whether in an outsourced or in-house processing model. In particular, CRO organizations can derive significant operational efficiencies and synergies with this solution to benefit our clients. The offering is easy to implement and set up, with a typical installation taking less than ten weeks.

On the other hand, PV Planner addresses the client’s resourcing management challenges by centralizing the function globally and providing insights into daily workloads, resource forecasts, and work completion based on available capacity. The solution leverages cognitive automation to recommend resource assignments based upon current and projected workloads, resource availability, geographic site, role, and complexity of work. RxLogix also can read product information from the incoming E2B R3 files through its PV EMA Plug-In product and a robust Risk Management solution through PV Risk Manager.

Lastly, RxLogix’ PV Register centralizes all Product and Study data management and registrations onto a single platform; PV DataHub and PV Gateway offer a single source of truth for all Intake, Signaling, and Analytical reporting needs, covering the end-to-end PV needs for the pharma companies.

Differentiated Global Safety Solution Strategy and Roadmap Services

In addition to their comprehensive product line, RxLogix has one competitive advantage over all others: they are on top of their game! “We avoid minor strategic errors that could ruin a pharmaceutical company,” says Raj. What is avoided? “Prolonged clinical trials, delayed product launches, restrictions in indications labeling, audit findings, or the need for multi-million-dollar investments for additional safety studies or clinical trials,” he answers. RxLogix believes that organizations can avoid or mitigate most of the challenges by having a safety solution strategy and roadmap of next-generation technologies that can help them achieve even greater operational excellence.

launches, restrictions in indications labeling, audit findings, or the need for multi-million-dollar investments for additional safety studies or clinical trials,” he answers. RxLogix believes that organizations can avoid or mitigate most of the challenges by having a safety solution strategy and roadmap of next-generation technologies that can help them achieve even greater operational excellence.